MedPacto Names Woo Jung-won CEO, Sharpens Focus on Tech Transfers and Trials

MedPacto, an innovative drug development company, has reorganized its CEO structure and appointed Woo Jung-won as chief executive to strengthen clinical development and technology transfer capabilities. Founder Kim Sung-jin resigned as CEO but will remain chairman. The move reflects a management shift aimed at focusing on clinical progress for key new drug programs and advancing technology transfer efforts. MedPacto also plans to pursue a clinical trial application for a new anticancer drug in the second half of the year. After the leadership change, the company’s clinical execution and technology transfer capabilities are expected to be key points to watch. Source: mk.co.kr